Anatara Lifesciences Ltd (ANR.AX)
- Previous Close
0.0460 - Open
0.0460 - Bid 0.0460 x 6348300
- Ask 0.0480 x 5187600
- Day's Range
0.0460 - 0.0480 - 52 Week Range
0.0207 - 0.0488 - Volume
506,975 - Avg. Volume
173,180 - Market Cap (intraday)
8.059M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
anataralifesciences.comRelated News
Performance Overview: ANR.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANR.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANR.AX
Valuation Measures
Market Cap
8.06M
Enterprise Value
6.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.36
Enterprise Value/Revenue
6.40
Enterprise Value/EBITDA
-3.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-65.37%
Return on Equity (ttm)
-117.14%
Revenue (ttm)
-123.18k
Net Income Avi to Common (ttm)
-1.75M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.08M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-948.77k
Research Analysis: ANR.AX
Company Insights: ANR.AX
ANR.AX does not have Company Insights